Adagene

ADAGNasdaq China Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$213.347 M

$3.23 +0.62%

Close of 22 Sept 2026

Revenue

$7.67M

#3208 by revenue

Earnings

-$17.6M

Loss-making

Shares outstanding

59,231,993

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#261Alx OncologyALXO$221.2M
#262Nervgen PharmaNGEN$219.7M
#263AdageneADAG$213.3M
#264NkartaNKTX$211.3M
#265PepGenPEPG$206.4M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Adagene, worth $92.3K. Grants and option exercises are excluded.

Cuong Do V$7.50K
2,000 shares at $3.75 on 14 Aug 2026 · filed 18 Aug 2026
Peter LuoChief Executive Officer$84.8K
23,245 shares at $3.65 on 4 Aug 2026 · filed 6 Aug 2026

What if Adagene were worth as much as…

Open the what-if tool →

Gold $30.2T

$457,732.63

Per share 141,713× higher

Bitcoin $1.74T

$26,368.10

Per share 8,163× higher

Nvidia $5.52T

$83,506.95

Per share 25,854× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Adagene are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.